REFERENCES

1. Grutzmann R, Post S, Saeger HD, et al. Intraductal papillary mucinous neoplasia (IPMN) of the pancreas: its diagnosis, treatment, and prognosis. Dtsch Arztebl Int 2011;108:788-94. DOI: 10.3238/arztebl.2011.0788 [ Links ]

2. Swartz MJ, Hsu CC, Pawlik TM, et al. Adjuvant chemoradiotherapy after pancreatic resection for invasive carcinoma associated with intraductal papillary mucinous neoplasm of the pancreas. Int J Radiat Oncol Biol Phys 2010;76:839-44. DOI: 10.1016/j.ijrobp.2009.02.071 [ Links ]

3. Tanaka M, Fernández-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 2012;12:183-97. DOI: 10.1016/j.pan.2012.04.004 [ Links ]

4. Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006;6:17-32. DOI: 10.1159/000090023 [ Links ]

5. Kim KW, Park SH, Pyo J, et al. Imaging features to distinguish malignant and benign branch-duct type intraductal papillary mucinous neoplasms of the pancreas: a meta-analysis. Ann Surg 2014;259:72-81. DOI: 10.1097/SLA.0b013e31829385f7 [ Links ]

6. Rei S, Nirav T, Srinadh A, et al. Diagnostic yield of endoscopic retrograde cholangiopancreatography-based cytology for distinguishing malignant and benign intraductal papillary mucinous neoplasm: systematic review and meta-analysis. Dig Endosc 2014;26:586-93. DOI: 10.1111/den.12230 [ Links ]

7. Uehara H, Ishikawa O, Katayama K, et al. Size of mural nodule as an indicator of surgery for branch duct intraductal papillary mucinous neoplasm of the pancreas during follow-up. J Gastroenterol 2011;46(5):657e63. DOI: 10.1007/s00535-010-0343-0 [ Links ]

8. Uehara H, Ishikawa O, Ikezawa K, et al. A natural course of main duct intraductal papillary mucinous neoplasm of the pancreas with lower likelihood of malignancy. Pancreas 2010;39(5):653e7. DOI: 10.1097/MPA.0b013e3181c81b52 [ Links ]

9. Kawada N, Uehara H, Nagata S, et al. Predictors of malignancy in branch duct intraductal papillary mucinous neoplasm of the pancreas. JOP 2014;15(5):459e64. [ Links ]

10. The European Study Group on Cystic Tumours of the Pancreas. European evidence-based guidelines on pancreatic cystic neoplasms. Gut 2018;0:1-16. DOI: 10.1136/gutjnl-2018-316027 [ Links ]

11. Vege S, Ziring B, Jain R, et al. American Gastroenterological Association Institute Guideline on the Diagnosis and Management of Asymptomatic Neoplastic Pancreatic Cysts. Gastroenterology 2015;148:819-22. DOI: 10.1053/j.gastro.2015.01.015 [ Links ]

12. Tanaka M, Castillo C, Kamisawa T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology 2017;17(5):738-53. [ Links ]

13. Yamaguchi K, Nakamura M, Shirahane K, et al. Pancreatic juice cytology in IPMN of the pancreas. Pancreatology 2005;5:416-21. DOI: 10.1159/000086555 [ Links ]

14. Adsay NV, Fukushima N, Furukawa T, et al. Intraductal neoplasm of the pancreas. In: Bosman FT, Carneiro F, Hruban RH, et al., eds. WHO classification of tumors of digestive system. Lyon: WHO Press; 2010. pp. 304-13. [ Links ]

15. Adarsh M, Jeffrey D, Tyler M. Post-endoscopic retrograde cholangiopancreatography pancreatitis. Gastroenterol Rep 2015;3(1):32-40. [ Links ]

16. Chen J, Wang XM, Liu XQ. Risk factors for post-ERCP pancreatitis: a systematic review of clinical trials with a large sample size in the past 10 years. Eur J Med Res 2014;19:26. [ Links ]

17. Jang JY, Park T, Lee S, et al. Validation of international consensus guidelines for the resection of branch duct-type intraductal papillary mucinous neoplasms. BJS 2014;101:686-92. DOI: 10.1002/bjs.9491 [ Links ]

18. Nagai K, Doi R, Ito T, et al. Single-institution validation of the international consensus guidelines for treatment of branch duct intraductal papillary mucinous neoplasms of the pancreas. J Hepatobiliary Pancreat Surg 2009;16:353-8. DOI: 10.1007/s00534-009-0068-8 [ Links ]

19. Brian K, Zhimin L, Damien M, et al. Evaluation of the Fukuoka Consensus Guidelines for intraductal papillary mucinous neoplasms of the pancreas: results from a systematic review of 1,382 surgically resected patients. Surgery 2015;158:1192-202. DOI: 10.1016/j.surg.2015.03.021 [ Links ]

20. Moris M, Wallace MB. Intraductal papillary mucinous neoplasms and mucinous cystadenomas: current status and recommendations. Rev Esp Enferm Dig 2017;109(5):358-67. DOI: 10.17235/reed.2017.4630/2016 [ Links ]

21. Fritz S, Hackert T, Hinz U, et al. Role of serum carbohydrate 19-9 and carcinoembryonic antigen in distinguishing between benign and invasive intraductal papillary mucinous neoplasm of the pancreas. Br J Surg 2011;98:104-10. DOI: 10.1002/bjs.7280 [ Links ]

22. Freeny PC, Saunders MD. Moving beyond morphology: new insights into the characterization and management of cystic pancreatic lesions. Radiology 2014;272:345-63. DOI: 10.1148/radiol.14131126 [ Links ]

23. Arima K, Okabe H, Hashimoto D, et al. The neutrophil-to-lymphocyte ratio predicts malignant potential in intraductal papillary mucinous neoplasms. J Gastrointest Surg 2015;19:2171-7. DOI: 10.1007/s11605-015-2973-2 [ Links ]

24. Goh B, Teo JY, Allen JC, et al. Preoperative platelet-to-lymphocyte ratio improves the performance of the international consensus guidelines in predicting malignant pancreatic cystic neoplasms. Pancreatology 2016;16:888-92. DOI: 10.1016/j.hpb.2016.02.058 [ Links ]

25. Hibi Y, Fukushima N, Tsuchida A, et al. Pancreatic juice cytology and sub-classification of intraductal papillary mucinous neoplasms of the pancreas. Pancreas 2007;34:197-204. DOI: 10.1097/MPA.0b013e31802dea0 [ Links ]

26. Kawada N, Uehara H, Nagata S, et al. Pancreatic juice cytology as sensitive test for detecting pancreatic malignancy in intraductal papillary mucinous neoplasm of the pancreas without mural nodule. Pancreatology 2016;16(5):853-8. DOI: 10.1016/j.pan.2016.07.011 [ Links ]

27. Ohtsuka T, Matsunaga T, Kimura H, et al. Role of pancreatic juice cytology in the preoperative management of intraductal papillary mucinous neoplasm of the pancreas in the era of international consensus guidelines. World J Surg 2014;38:2994-3001. DOI: 10.1007/s00268-014-2684-y [ Links ]

28. Sai JK, Nobukawa B, Matsumura Y, et al. Pancreatic duct lavage cytology with the cell block method for discriminating benign and malignant branch-duct type intraductal papillary mucinous neoplasms. Gastrointest Endosc 2013;77:726-35. DOI: 10.1016/j.gie.2012.11.008 [ Links ]

29. Hirono S, Tani M, Kawai M, et al. The carcinoembryonic antigen level in pancreatic juice and mural nodule size are predictors of malignancy for branch duct type intraductal papillary mucinous neoplasms of the pancreas. Ann Surg 2012;255:517-22. [ Links ]

30. Kondo H, Sugano K, Fukayama N, et al. Detection of K-ras gene mutations at codon 12 in the pancreatic juice of patients with intraductal papillary mucinous tumors of the pancreas. Cancer 1997;79:900-5. DOI: 10.1002/(SICI)1097-0142(19970301)79:5<900::AID-CNCR5>3.0.CO;2-F. [ Links ]

31. Jiang P, Watanabe H, Okada G, et al. Diagnostic utility of aberrant methylation of tissue factor pathway inhibitor 2 in pure pancreatic juice for pancreatic carcinoma. Cancer Sci 2006;97:1267-73. DOI: 10.1111/j.1349-7006.2006.00308.x [ Links ]

32. Watanabe H, Okada G, Ohtubo K, et al. Expression of mesothelin mRNA in pure pancreatic juice from patients with pancreatic carcinoma, intraductal papillary mucinous neoplasm of the pancreas, and chronic pancreatitis. Pancreas 2005;30:349-54. DOI: 10.1097/01.mpa. 0000160281.56828.76 [ Links ]

33. Shimamoto T, Tani M, Kawai M, et al. MUC1 is a useful molecular marker for malignant intraductal papillary mucinous neoplasms in pancreatic juice obtained from endoscopic retrograde pancreatography. Pancreas 2010;39:879-83. DOI: 10.1097/MPA.0b013e3181d6ba04 [ Links ]